Time filter

Source Type

Patent
SUN PHARMACEUTICAL INDUSTRIES Ltd | Date: 2016-10-28

This disclosure provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units, wherein said capsule dosage form is bioequivalent to the marketed ToprolXL tablet. The extended-release capsule dosage form comprising coated discrete units can be sprinkled onto food to ease administration to patients who have difficulty swallowing tablets or capsules.


Patent
Sun Pharmaceutical Industries Ltd. | Date: 2016-09-09

The present invention relates to novel oral sustained release pharmaceutical dosage forms for delivery of budesonide to the lower gastrointestinal tract for the treatment of Crohns disease.


Patent
SUN PHARMACEUTICAL INDUSTRIES Ltd | Date: 2016-08-10

The present invention relates to sustained release oral pharmaceutical compositions of tofacitinib comprising tofacitinib, a release controlling polymer, and pharmaceutically acceptable excipients, wherein the sustained release oral pharmaceutical compositions further comprise an outer modified release coating that includes a modified release polymer. The invention also relates to a process for the preparation of the compositions.


Patent
SUN PHARMACEUTICAL INDUSTRIES Ltd | Date: 2016-05-06

The present invention relates to extended release liquid compositions of guanfacine. The extended release liquid compositions of the present invention are bioequivalent to marketed extended release tablet compositions of guanfacine. Said extended release liquid compositions provide substantially similar in-vitro dissolution release profile upon storage for at least seven days. Further, the extended release liquid compositions are stable. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions.


Patent
SUN PHARMACEUTICAL INDUSTRIES Ltd | Date: 2016-05-02

The present invention relates to oral liquid compositions of guanfacine. The liquid. compositions can be immediate release or extended release compositions. The compositions comprise guanfacine in a concentration from about 0.1 mg/mL to about 12.0 mg/mL of the composition. The liquid compositions can be in the form of ready-to use liquid compositions or reconstituted liquid compositions. It further relates to processes for the preparation of said oral liquid compositions.


Patent
SUN PHARMACEUTICAL INDUSTRIES Ltd | Date: 2016-02-01

The present invention provides an extended-release capsule dosage form of metoprolol succinate in the form of coated discrete units and processes for their preparation.


Patent
SUN PHARMACEUTICAL INDUSTRIES Ltd | Date: 2016-06-01

The present invention relates to pharmaceutical compositions comprising dimethyl fumarate and a pharmaceutically acceptable agent which inhibits the enzyme catalyzed degradation of dimethyl fumarate.


Patent
SUN PHARMACEUTICAL INDUSTRIES Ltd | Date: 2016-02-02

The present invention relates to a once daily pharmaceutical composition comprising doxycycline and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition exhibits a reduced food effect. The invention further provides a method of treatment of rosacea by administering to a person in need thereof the doxycycline pharmaceutical composition with or without food. A process of preparing such pharmaceutical composition is also provided.


Patent
SUN PHARMACEUTICAL INDUSTRIES Ltd | Date: 2016-02-02

The present invention relates to a once daily pharmaceutical composition comprising doxycycline, a controlled-release polymer, and one or more pharmaceutically acceptable excipients. The invention further provides a method of treatment of rosacea by administering such pharmaceutical composition. A process of preparing such pharmaceutical composition is also provided.


Patent
Sun Pharmaceutical Industries Ltd. | Date: 2016-06-17

A method of treating a patient in need of therapy with fentanyl or a salt thereof, the method comprising providing a ready-to-administer solution consisting essentially of fentanyl or a salt thereof as the sole active ingredient, a sugar or sugar alcohol and water for injection, the solution having a pH in the range of 3.5 to 7.5, and parenterally administering the solution to the patient.

Loading Sun Pharmaceutical Industries Ltd. collaborators
Loading Sun Pharmaceutical Industries Ltd. collaborators